ReviewNanomaterials (Basel, Switzerland)2022
Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins.
Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Sustainable Nanotechnology Approaches for Rapid Food Contaminant Detection and Future Food Safety Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Bimetallic nano mixtures enable rapid ultrasensitive detection of high risk HPV for early cervical cancer diagnosis.Discover nano · 2026Article
- Development of MoSLife (Basel, Switzerland) · 2026Article
- Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox.Journal of nanobiotechnology · 2026Review
- Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.PloS one · 2026Article
- A Scoring Function for Monolayer-Protected Gold Nanoparticles Capable of Recognizing Small Organic Molecules in Solution.Journal of chemical theory and computation · 2025Article
- Review
- Nanomaterials for biomedical applications.Beilstein journal of nanotechnology · 2025Article
- Single-Domain Antibody-Gold Nanoparticle Bioconjugates as Immunosensors for the Detection of Hantaviruses.Molecular diagnosis & therapy · 2024Article
- Review
- Review
- Lateral Flow Assays Biotesting by Utilizing Plasmonic Nanoparticles Made of Inexpensive Metals - Replacing Colloidal Gold.bioRxiv : the preprint server for biology · 2024Article
- Enhancing the Sensitivity of Lateral Flow Assay with Europium Nanoparticles for Accurate Human IgG Quantification.Micromachines · 2023Article
- A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors.Current issues in molecular biology · 2023Review
- Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis.Biosensors · 2022Review
- Review
- Protein biomarker discovery in neural tissue: a comparative analysis of immunoassay and colloidal gold lateral flow assay method.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses, that are now well-known to the public, include a family of viruses that can cause severe acute respiratory syndrome (SARS) and other respiratory diseases, such as Middle East respiratory syndrome (MERS). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh member of this coronavirus family, was detected in 2019 and can cause a number of respiratory symptoms, from dry cough and fever to fatal viral pneumonia. Various diagnostic assays ranging from real-time polymerase chain reaction (RT-PCR) to point-of-care medical diagnostic systems have been developed for detection of viral components or antibodies targeting the virus. Point-of-care assays allow rapid diagnostic assessment of infectious patients. Such assays are ideally simple, low-cost, portable tests with the possibility for on-site field detection that do not require skilled staff, sophisticated equipment, or sample pretreatment, as compared to RT-PCR. Since early 2021 when new SARS-CoV-2 variants of concern increased, rapid tests became more crucial in the disease management cycle. Among rapid tests, gold nanoparticle (GNP)-based lateral flow assays (LFAs) have high capacity for performing at the bedside, paving the way to easy access to diagnosis results. In this review, GNP-based LFAs used for either COVID-19 proteins or human response antibodies are summarized and recommendations for their improvement have been suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.